poisar

Stocks · News reference

8-K filing — Revolution Medicines, Inc. (RVMDW)

Aug 26, 2026, 5:33 PMSEC EDGAR

Filed: 2026-08-26 AccNo: 0001193125-26-366931 Size: 178 KB Item 8.01: Other Events

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RVMDW
Source
edgar
Observed
Aug 26, 2026, 5:33 PM
Checked
Aug 26, 2026, 5:33 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 26, 2026, 10:17 PMNot Specified

    Onco360® Has Been Selected as a National Pharmacy Partner for RASONQUE™ (daraxonrasib)

    Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Revolution Medicines for the launch of RASONQUE (daraxonrasib), a RAS GTPase inhibitor for metastatic pancreatic adenocarcinoma. The drug showed significant clinical benefits in the phase 3 RASolute-302 trial, with median PFS of 7.3 months and OS of 13.2 months in RAS G12 mutation patients compared to 3.5 months and 6.6 months respectively for chemotherapy.

    Read original at globenewswire-inc
    RVMDRVMDW
  2. Aug 26, 2026, 4:59 PMRevolution Medicines, Inc.

    U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

    The FDA has approved RASONQUE (daraxonrasib), developed by Revolution Medicines, as the first targeted RAS inhibitor for treating metastatic pancreatic adenocarcinoma in patients who have received prior systemic therapy or are not candidates for multiagent chemotherapy. In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% compared to chemotherapy, with median overall survival of 13.2 months versus 6.7 months, and demonstrated manageable safety with improved quality of life measures.

    Read original at globenewswire-inc
    RVMDRVMDW
  3. Aug 7, 2026, 7:44 PMHagens Berman

    ERAS 3-DAY DEADLINE ALERT: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman

    Hagens Berman is investigating securities fraud claims against Erasca, Inc. for allegedly misleading investors about its lead oncology drug ERAS-0015's competitive advantages, safety profile, and intellectual property protections. The company faces patent infringement allegations from Revolution Medicines and reported a patient death in clinical trials, triggering a $2.8 billion market capitalization loss. Investors with substantial losses can serve as lead plaintiffs with an August 10, 2026 deadline.

    Read original at globenewswire-inc
    ERASRVMDRVMDW